SPRY · Insider Trading
ARS Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by SPRY officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | Donn Casale | President and CEO | A | +1,036,923 deriv. | — |
| 2026-09-02 | Margaret Ekins Smith | Chief Commercial Officer | A | +1,001,738 deriv. | — |
| 2026-07-02 | Donn Casale | President | A | +898,456 deriv. | — |
| 2026-06-26 | Brent L Saunders | Director | A | +30,000 deriv. | — |
| 2026-06-26 | Laura Shawver | Director | A | +30,000 deriv. | — |
| 2026-06-26 | Saqib Islam | Director | A | +30,000 deriv. | — |
| 2026-06-26 | Michael Kelly | Director | A | +30,000 deriv. | — |
| 2026-06-26 | Phillip M Schneider | Director | A | +30,000 deriv. | — |
| 2026-06-26 | Peter A. Thompson | Director | A | +30,000 deriv. | — |
| 2026-06-26 | Rajeev Dadoo | Director | A | +30,000 deriv. | — |
| 2026-06-26 | Pratik Shah | Director | A | +30,000 deriv. | — |
| 2026-06-26 | RA Capital Healthcare Fund LP | Director | A | +150,000 deriv. | — |
| 2026-06-12 | Alexander A Fitzpatrick | Chief Legal Officer | Sell | −3,355 | −$33.55K |
| 2026-06-12 | Eric Karas | Chief Commercial Officer | MIXED | — | −$212.50K |
| 2026-01-05 | Kathleen D. Scott | Chief Financial Officer | A | +240,000 deriv. | — |
| 2026-01-05 | Justin Chakma | Chief Business Officer | A | +240,000 deriv. | — |
| 2026-01-05 | Brian Dorsey | Chief Operating Officer | A | +240,000 deriv. | — |
| 2026-01-05 | Eric Karas | Chief Commercial Officer | A | +240,000 deriv. | — |
| 2026-01-05 | Alexander A Fitzpatrick | Chief Legal Officer | A | +240,000 deriv. | — |
| 2026-01-05 | Richard E Lowenthal | PRESIDENT AND CEO | A | +1,115,000 deriv. | — |
| 2026-01-05 | Sarina Tanimoto | CHIEF MEDICAL OFFICER | A | +1,115,000 deriv. | — |
| 2025-11-14 | Justin Chakma | Chief Business Officer | MIXED | −136,380 | −$1.45M |
| 2025-11-14 | Pratik Shah | Director | G | −350,000 | — |
| 2025-11-14 | Brian Dorsey | Chief Operating Officer | MIXED | — | −$176.08K |
| 2025-08-22 | Richard E Lowenthal | PRESIDENT AND CEO | Sell | −50,000 | −$724.35K |
| 2025-08-22 | Kathleen D. Scott | Chief Financial Officer | MIXED | — | −$168.75K |
| 2025-08-21 | Sarina Tanimoto | CHIEF MEDICAL OFFICER | Sell | −50,000 | −$703.76K |
| 2025-07-03 | Eric Karas | Chief Commercial Officer | MIXED | — | −$232.36K |
| 2025-07-01 | Deerfield Mgmt III, L.P. | 10%+ Owner | Sell | −4,440,894 | −$81.98M |
| 2025-06-27 | Phillip M Schneider | Director | A | +30,000 deriv. | — |
| 2025-06-27 | Laura Shawver | Director | A | +30,000 deriv. | — |
| 2025-06-27 | Saqib Islam | Director | A | +30,000 deriv. | — |
| 2025-06-27 | Pratik Shah | Director | A | +30,000 deriv. | — |
| 2025-06-27 | Peter A. Thompson | Director | A | +30,000 deriv. | — |
| 2025-06-27 | Rajeev M. Shah | Director | A | +150,000 deriv. | — |
| 2025-06-27 | Rajeev Dadoo | Director | A | +30,000 deriv. | — |
| 2025-06-27 | Brent L Saunders | Director | A | +30,000 deriv. | — |
| 2025-06-27 | Michael Kelly | Director | A | +30,000 deriv. | — |
| 2025-06-20 | Eric Karas | Chief Commercial Officer | MIXED | — | −$217.50K |
| 2025-05-22 | Brent L Saunders | Director | MIXED | — | −$1.59M |
| 2025-05-22 | Kathleen D. Scott | Chief Financial Officer | MIXED | — | −$630.16K |
| 2025-05-22 | Alexander A Fitzpatrick | Chief Legal Officer | MIXED | −2,969 | −$893.51K |
| 2025-04-08 | Laura Shawver | Director | MIXED | — | −$372.56K |
| 2025-03-21 | Eric Karas | Chief Commercial Officer | MIXED | — | −$125.00K |
| 2025-03-07 | Laura Shawver | Director | MIXED | — | −$317.95K |
| 2025-02-04 | Laura Shawver | Director | MIXED | — | −$388.47K |
| 2025-01-07 | Laura Shawver | Director | MIXED | — | −$397.56K |
| 2025-01-03 | Eric Karas | Chief Commercial Officer | A | +152,300 deriv. | — |
| 2025-01-03 | Justin Chakma | Chief Business Officer | A | +274,100 deriv. | — |
| 2025-01-03 | Kathleen D. Scott | Chief Financial Officer | A | +176,700 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Richard E Lowenthal | PRESIDENT AND CEO | 13,186,389 | $51.69M |
| Sarina Tanimoto | CHIEF MEDICAL OFFICER | 12,292,712 | $48.19M |
| RA Capital Healthcare Fund LP | Director | 9,452,119 | $37.05M |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 10%+ Owner | 5,257,329 | $20.61M |
| Deerfield Mgmt III, L.P. | 10%+ Owner | 4,887,254 | $19.16M |
| Pratik Shah | Director | 4,474,554 | $17.54M |
| Rajeev Dadoo | Director | 3,009,677 | $11.80M |
| Rajeev M. Shah | Director | 902,904 | $3.54M |
| Peter A. Thompson | Director | 269,323 | $1.06M |
| Laura Shawver | Director | 260,348 | $1.02M |
| Justin Chakma | Chief Business Officer | 136,380 | $534.61K |
| Alexander A Fitzpatrick | Chief Legal Officer | 90,910 | $356.37K |
| Michael Kelly | Director | 83,225 | $326.24K |
| Kathleen D. Scott | Chief Financial Officer | 18,292 | $71.70K |
| Eric Karas | Chief Commercial Officer | 12,176 | $47.73K |
| Brian Dorsey | Chief Operating Officer | 10,789 | $42.29K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SPRY quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.